Are you ready for trial virtualization?

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

4 jahre vor

Html
Text

Learn More

This week's Fierce Biotech is brought to you by Medidata Solutions.
Trouble viewing? Click here.

The COVID-19 pandemic drove 45% of clinical trial sites to transition patients from in-person to remote visits using virtual trial solutions. 1 Disruptions preventing or limiting site access to patients, monitors, and CRAs are propelling long-lasting changes in the research industry, supported by the adoption of virtualization technologies. Are you prepared to adopt a virtualization strategy? Can you respond to urgent remote requirements for patients and sites? Have you and your CRO evolved your technology approach to support fully remote study conduct? Will your strategy meet future standards for transforming trials? Begin your three-minute assessment across 8 parameters today.

To get additional information about the capabilities driving a successful response and approach to virtualization, download the eBook now. 1. Medidata: Clinical Trial Sites Share Frontline Insights into COVID-19 Impact


Privacy Policy • Trademarks • Legal Copyright © 2020 Medidata Solutions, Inc. 350 Hudson St, 9th Floor, New York, NY 10014 1-866-MEDIDATA (633-4328) • medidata.com

If you no longer wish to receive communications from Medidata Solutions, please opt out here.

Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.

You are currently subscribed as [email protected].
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.

Are you ready for trial virtualization?

Teilen auf

Weitere Newsletter von Fiercebiotech.com

Verwandte Newsletter